Autoreactive CD4+ T-cell receptor complex (TCR complex)

The autoreactive CD4+ T-cell receptor (TCR) complex is a multi-subunit protein assembly on the surface of CD4+ T lymphocytes that inappropriately recognizes self-antigens presented by Major Histocompatibility Complex (MHC) class II molecules (Janeway's Immunobiology, 9th Ed). This complex is composed of a variable TCR alpha/beta heterodimer, which determines antigen specificity, and invariant CD3 subunits (gamma, delta, epsilon, and zeta) that are essential for signal transduction (UniProt P04234, P07766). In autoimmune conditions, these receptors bypass central and peripheral tolerance mechanisms, triggering an immune attack against the body's own tissues, such as the insulin-producing cells in the pancreas or the myelin sheath in the central nervous system (PubMed PMID: 30324771). As a therapeutic target, the complex is modulated to suppress these harmful immune responses without causing global immunosuppression. Drugs like Teplizumab target the CD3 epsilon component of the complex to induce a state of T-cell unresponsiveness or exhaustion in autoreactive populations (FDA, 2022). This targeted approach aims to preserve organ function and delay disease progression in patients with conditions like Type 1 Diabetes.

Other names

Autoreactive TCRSelf-reactive T-cell receptorMHC-II restricted T-cell receptor complexCD4+ TCR-CD3 complexAutoreactive CD4+ T cell T-cell receptor complex

Modulation of T-cell receptor signaling through binding to the CD3 epsilon subunit, induction of immunological tolerance or anergy in autoreactive T-cell populations, and competitive inhibition of the TCR-MHC-peptide interaction.